Locations:
Search IconSearch
March 19, 2018/Cancer

New AJCC TNM Edition More Accurately Predicts Recurrence in Pulmonary Carcinoid Tumors

Turn to 8th edition for better correlation

PrimaryPulmonaryCarcinoid

By Josephine Dermawan, MD, PhD, and Carol Farver, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Pulmonary carcinoid tumors are the uncommon, clinically indolent relative of non-small cell lung cancer (NSCLC). Because current lung cancer staging guidelines are largely based on data from NSCLC, which is vastly more common, using American Joint Committee on Cancer (AJCC) TNM staging to predict long-term recurrence and survival for carcinoid tumors is unclear at best and controversial for most. Our research team sought to offer some clarity to this controversy through a single-institution study that correlates pathologic stage from both the 7th and 8th editions of the Staging Manual with clinical outcomes for carcinoid tumors. We presented our findings at the 2018 Annual Meeting of the United States and Canadian Academy of Pathology.

We identified 217 surgical lung resection cases from 1995-2015 with a diagnosis of primary lung carcinoid tumors and staged them according to both the 7th and 8th editions of the AJCC TNM Classification of Lung Tumors. We also collected clinical data, including demographics, smoking history, recurrence and survival. Patients with concurrent or preexisting malignancies and/or positive resection margins were excluded.

Of the 181 cases available for clinical follow-up, 16 experienced recurrence (9 percent) and five (3 percent) died with metastatic carcinoid tumor. Atypical carcinoid tumors were more significantly likely to recur (log-rank P < 0.0001). Because the 8th edition of TNM places more emphasis on tumor size, staging based on this edition was more likely than the 7th edition to predict outcomes in our study (P < 0.0001 vs P = 0.0026). Procedure type and smoking history did not correlate with outcomes.

Advertisement

Based on our study, we recommend the criteria in the 8th edition of AJCC’s TNM Classification of Lung Tumors for stating primary lung carcinoid tumors. Classifying carcinoid tumors based on typical versus atypical histology types, which is based on mitotic figure counts on histology, is still the best predictor of tumor recurrence. We are currently examining the applicability of the ki67 proliferative index as another tool for classifying this tumor and predicting tumor recurrence.

Advertisement

Related Articles

Dr. Melenhorst
April 24, 2025/Cancer/News & Insight
Explore Developments in CAR T-Cell Therapy for CLL (Podcast)

Discussing research into improving CAR T-cell therapy efficacy

Dr. Cherian
April 23, 2025/Cancer/News & Insight
De-intensifying Radiation Therapy in Low-Risk Breast Cancer

Ultra-Hypofractionated Whole Breast Irradiation and Partial Breast Irradiation Reduce Many Toxicities

Pathology image
April 22, 2025/Cancer/News & Insight
Patient Case Study: Second Opinion Reveals Misdiagnosed Cancer

Patient receives liver transplant and a new lease on life

Clinician talking with patient
April 21, 2025/Cancer/News & Insight
Hematology Clinic Created to Support Spanish-Speaking Population

Lutheran Hospital team brings emerging treatments to community setting

Dr. Pennell and patient
April 10, 2025/Cancer/News & Insight
BiTE Therapy Emerges for Treating Small-Cell Lung Cancer

Hybrid treatment model helps improve cancer care access

Immune checkpoint inhibitor illustration
April 8, 2025/Cancer
Building on Initial Trial Data about New Immune Checkpoint Inhibitor for Treating Colorectal Cancer

Insights indicate that treatment may be beneficial beyond MSI-H tumors

Dr. Gerds with a patient
April 7, 2025/Cancer/News & Insight
Positive Results from Prospective, Randomized, Phase 3 Registrational Trial of Pelabresib + Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis

Combination therapy doubles the number of meaningful spleen volume responses over monotherapy

Baby's feet
April 3, 2025/Cancer/News & Insight
Fertility Preservation Counseling for Young Adults with Cancer

Growing need for addressing fertility concerns

Ad